ASXL1 and myelodysplastic syndrome: Compared to MDS patients without TP53 mutations, ASXL1, RUNX1, U2AF1, JAK2, and SF3B1 are less detectable in TP53 mutant cases, in contrast to TET2, which is more frequent in TP53 mutation patients [15].